TORONTO, March 18, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") today announced the following:
Appointment of a new US Sales Agent, opening order of 100 Pulsewave™
Clear2there LLC, a leading provider of advanced video surveillance,
smart-home, smart-business, communications, and machine-to-machine
(M2M) solutions for service providers and enterprises, announced it has
joined forces with Biosign to address the burgeoning market for smart
healthcare and monitoring solutions.
As a part of a sales agency agreement with Biosign, Clear2there will
begin offering Biosign's Pulsewave™ medical device technology across
the North American market. Under the terms of the agreement,
Clear2there plans to integrate the Pulsewave™ software client with
their Viewbiquity Content Interface as well as their Edge Gateway
device. Clear2there will offer the joint solution as a part of a
highly-regarded smart services package being delivered to subscribers
by local telephone and data service providers across North America.
Biosign's FDA-cleared Pulsewave™ monitor captures blood pressure and
heart rate readings and will leverage the Viewbiquity Cloud Application
Suite provided by Clear2there for connectivity to the Biosign Cloud
Diagnostics™ services platform. Initially, Clear2there plans to deploy
up to one hundred Pulsewave™ devices and activate the related
monitoring services as a part of its ongoing program of service
provider evaluation currently underway in over 65 Viewbiquity pilot
projects in the United States.
"In our conversations with many local service providers, we have
observed a sharp increase in demand for smart health monitoring and
other telemedicine services that enable people to remain in their homes
as they age," said Craig Steen, president and chief executive officer
of Clear2there. "Biosign's Pulsewave™ product is a highly recognized
vital signs measurement solution that is very easy to use by both
seniors and people with disabilities.
The Biosign Pulsewave™ Monitor is an end-to-end solution for
non-invasive monitoring, analysis and reporting of health data. The
Pulsewave™ cuff painlessly captures the pulse waveform from a person's
radial artery and transmits it to the secure Biosign servers in the
cloud, in this case through the Viewbiquity Edge Gateway at the
consumer's home. Biosign algorithms are employed to analyze the data in
seconds in order to generate reports that include blood pressure and
other vital sign measurements. In addition, online Pulsewave™ analysis
and reporting tools give patients and healthcare providers secure
access to real-time and historical health information.
According to Biosign chief executive officer Robert Kaul, the data
collected during an examination can provide the basis for precise blood
pressure results as well as a broad range of other cardiovascular
measurements. "During a simple and painless user-initiated session, in
addition to blood pressure, the Pulsewave™ system can determine pulse
rate and variability, and can also detect anomalies in circulatory
function that may lead to a doctor's consultation," said Kaul. "The
data is not only analyzed as quickly as it is received, but historical
measurements can be charted and analyzed for trends and changes that
may indicate a need for medical intervention or attention, making the
system an excellent screening tool."
"Smart-healthcare and monitoring is one of the fastest growing segments
in this marketplace, and we are excited to enable local service
providers to meet their customers' needs with an innovative solution
such as Pulsewave™," noted Steen. "We anticipate that there will be
intense interest in this solution from consumers and family members who
seek a safe, reliable and flexible solution to monitor the well-being
of loved ones."
Clear2there is an innovative, full-service provider of market-leading
smart-home and smart-business solutions for service providers and
feature-rich video surveillance, communications, and M2M solutions for
businesses. Based in Oklahoma City and Deerfield Beach, Florida,
Clear2there works with national distribution partners, and offers a
team of dedicated support staff to assist in all phases of
implementation. For additional information, visit www.clear2there.com.
Appointment of new CFO:
The Company announced that it has appointed Mr. William Randolph (Randy)
Polley, CA as Chief Financial Officer, to replace Mr. Frank Iadipaolo,
CA who had earlier submitted his resignation in order to spend more
time on his other business interests.
Mr. Polley will oversee Biosign's finance and accounting functions,
utilizing extensive financial management and corporate development
experience gained through working with small and mid-sized firms in the
technology and healthcare sectors. He previously served as CFO and head
of Business Development for Rimax Health, operating as the Cosmetic
Surgery Hospital, as well as Director of Tricounsel Global Investments
Fund (TGIF), a "fund of funds". Mr. Polley has also acted in a senior
role as Chief Accountant and CFO of Daiwa Securities in Toronto, and
was a senior auditor at Arthur Andersen in Toronto. He holds an MBA
degree from York University, is a member of the Institute of Chartered
Accountants of Ontario and is a graduate of the Canadian Securities
Biosign's CEO Mr. Robert Kaul stated, "We are very pleased to welcome
Mr. Polley to Biosign as our new CFO. He brings us specific healthcare
and business development experience which we will need as we move
forward with our plans to launch our Heart Friendly™ brand in the US
market. Meanwhile, I would like to thank Mr. Iadipaolo for his service
to the Company. He has helped guide Biosign through our intense
restructuring period, and his dedication, skill, probity and
professionalism are greatly appreciated. We wish him all the best in
his future endeavours."
About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, computer
enabled biomedical systems and devices. Key applications include the
noninvasive monitoring of vital signs including blood pressure, pulse
rate and breathing rate, enhanced with web services. The Company's
UFIT® medical device technology powers quality data collection for
clinical decision support, self-care, wellness and disease management,
while it's Healthanywhere™ Suite offers industry-leading remote patient
monitoring solutions. For more information on Biosign, please visit www.biosign.com
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE: Biosign Technologies Inc.
For further information:
Biosign Contact Information
Robert Kaul, CEO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 234